Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Lorbrena / Lorviqua (lorlatinib by Year
Lorbrena / Lorviqua (lorlatinib — ALK+ NSCLC) — International reported YoY (%) (%)
Pfizer Lorbrena / Lorviqua (lorlatinib: 45.0% in FY2025, up 10.0 pts from a year earlier.
Latest, FY2025
45.0%
Period ended Dec 31, 2025
Change on a year earlier
+10.0 pts
35.0% in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Lorbrena | 1,023 | 731 | 40% | 40% | 407 | 306 | 33% | 616 | 424 | 45% | 44%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lorbrena / Lorviqua (lorlatinib — ALK+ NSCLC) — International reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 45.0% | +10.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 35.0% | -55.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 90.0% | +57.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2022 | Dec 31, 2022 | 33.0% | -2.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 35.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗ |
Cite this data
StockData. (2026). Pfizer Lorbrena / Lorviqua (lorlatinib (%), annual FY2021–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/lorbrena-yoy-intl
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.